This will enable the development of a standardizedsiRNA platform with 3′ end modifications targeting varioussequences, giving rise to improved nucleic acid-based drugs targetingFOLR1-low expressing cancers, kidney tubular epithelial cells, andmacrophages. This study provides a usefulframework for developing siRNAs against diseases caused by abnormalgene expression in FOLR1-expressing cells and new ligand-binding siRNAplatforms. The gene discussed is FOLR1; the disease is cancer.